4.7 Article

Natural History of Functional Tricuspid Regurgitation Quantified by Cardiovascular Magnetic Resonance

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 76, Issue 11, Pages 1291-1301

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2020.07.036

Keywords

cardiovascular magnetic resonance; natural history; prognosis; tricuspid regurgitation; tricuspid valve

Ask authors/readers for more resources

BACKGROUND Quantitation of tricuspid regurgitant (TR) severity can be challenging with conventional echocardiographic imaging and may be better evaluated using cardiovascular magnetic resonance (CMR). OBJECTIVES In patients with functional TR, this study sought to examine the relationship between TR volume (TRVol) and TR fraction (TRF) with all-cause mortality. METHODS We examined 547 patients with functional TR using CMR to quantify TRVol and TRF. The primary outcome was all-cause mortality. Thresholds for mild, moderate, and severe TR were derived based on natural history outcome data. RESULTS During a median follow-up of 2.6 years (interquartile range: 1.7 to 3.3 years), there were 93 deaths, with an estimated 5-year survival of 79% (95% confidence interval [CI]: 73% to 83%). After adjustment of clinical and imaging variables, including RV function, both TRF (adjusted hazard ratio [AHR] per 10% increment: 1.26; 95% CI: 1.10 to 1.45; p = 0.001) and TRVol (AHR per 10-ml increment: 1.15; 95% CI: 1.04 to 1.26; p = 0.004) were associated with mortality. Patients in the highest-risk strata of TRVol >= 45 ml or TRF >= 50% had the worst prognosis (AHR: 2.26; 95% CI: 1.36 to 3.76; p = 0.002 for TRVol and AHR: 2.60; 95% CI: 1.45 to 4.66; p = 0.001 for TRF). CONCLUSIONS This is the first study to use CMR to assess independent prognostic implications of functional TR. Both TRF and TRVol were associated with increased mortality after adjustment for clinical and imaging covariates, including right ventricular ejection fraction. A TRVol of >= 45 ml or TRF of >= 50% identified patients in the highest-risk strata for mortality. These CMR thresholds should be used for patient selection in future trials to determine if tricuspid valve intervention improves outcomes in this high-risk group. (C) 2020 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Cardiac & Cardiovascular Systems

Commentary: There is strength in heart teams, whether or not the numbers add up

Moritz C. Wyler von Ballmoos, Michael J. Reardon

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2023)

Editorial Material Cardiac & Cardiovascular Systems

Predicting a Changing Future

Michael J. Reardon

SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY (2023)

Article Cardiac & Cardiovascular Systems

Transcatheter aortic valve implantation in patients with bicuspid valve morphology: a roadmap towards standardization

Tian-Yuan Xiong, Walid Ben Ali, Yuan Feng, Kentaro Hayashida, Hasan Jilaihawi, Azeem Latib, Michael Kang-Yin Lee, Martin B. Leon, Raj R. Makkar, Thomas Modine, Christoph Naber, Yong Peng, Nicolo Piazza, Michael J. Reardon, Simon Redwood, Ashok Seth, Lars Sondergaard, Edgar Tay, Didier Tchetche, Wei-Hsian Yin, Mao Chen, Bernard Prendergast, Darren Mylotte

Summary: The indications for transcatheter aortic valve implantation (TAVI) have expanded to include low surgical risk and bicuspid aortic valve (BAV) patients, although BAV patients have been excluded from major randomized trials due to anatomical considerations. Despite advances in device design, BAV presents anatomical challenges and geographical variations, making it a challenging cohort for TAVI procedures.

NATURE REVIEWS CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Site-Level Variation and Predictors of Permanent Pacemaker TAVR in the Evolut Low-Risk Trial

Hemal Gada, Amit N. Vora, Gilbert H. L. Tang, Mubashir Mumtaz, John K. Forrest, Roger J. Laham, Steven J. Yakubov, G. Michael Deeb, Chad Rammohan, Jian Huang, Michael J. Reardon

Summary: We investigated predictors of permanent pacemaker implantation (PPI) after self-expanding transcatheter aortic valve replacement (TAVR), explored the variability of PPI rates across different sites, and examined the impact of implantation methods on PPI. Despite the advantages of TAVR compared to surgical aortic valve replacement, increased PPI remains a limitation. The study included 699 patients without baseline PPI and analyzed their clinical, echocardiographic, and procedural characteristics. The results showed significant site-to-site variability in PPI rates and identified baseline conduction disorders and implant depth as important predictors of PPI in low-risk TAVR patients with Evolut valves.

CARDIOVASCULAR REVASCULARIZATION MEDICINE (2023)

Article Immunology

Modern Outcomes After Liver Retransplantation: A Single-center Experience

Ashton A. Connor, Ashish Saharia, Constance M. Mobley, Mark J. Hobeika, David W. Victor, Sudha Kodali, Elizabeth W. Brombosz, Edward A. Graviss, Duc T. Nguyen, Linda W. Moore, A. Osama Gaber, R. Mark Ghobrial

Summary: The study retrospectively evaluated the outcomes of liver retransplantation and found that overall and graft survival rates were comparable to those of primary liver transplantation, indicating that modern liver retransplantation is a safer option for patients with liver graft failure.

TRANSPLANTATION (2023)

Article Cardiac & Cardiovascular Systems

Structural Valve Deterioration After Self-Expanding Transcatheter or Surgical Aortic Valve Implantation in Patients at Intermediate or High Risk

Daniel O'Hair, Steven J. Yakubov, Kendra J. Grubb, Jae K. Oh, Saki Ito, G. Michael Deeb, Nicolas M. Van Mieghem, David H. Adams, Tanvir Bajwa, Neal S. Kleiman, Stanley Chetcuti, Lars Sondergaard, Hemal Gada, Mubashir Mumtaz, John Heiser, William M. Merhi, George Petrossian, Newell Robinson, Gilbert H. L. Tang, Joshua D. Rovin, Stephen H. Little, Renuka Jain, Sarah Verdoliva, Tim Hanson, Shuzhen Li, Jeffrey J. Popma, Michael J. Reardon

Summary: This study aimed to evaluate the 5-year incidence and clinical outcomes of hemodynamic structural valve deterioration (SVD) in patients undergoing self-expanding transcatheter aortic valve implantation (TAVI) or surgery. The results showed a lower rate of SVD in the TAVI group and its association with worse clinical outcomes.

JAMA CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

TAVR in 2023: Who Should Not Get It?

Sukhdeep Bhogal, Toby Rogers, Amer Aladin, Itsik Ben-Dor, Jeffrey E. Cohen, Christian C. Shults, Jason P. Wermers, Gaby Weissman, Lowell F. Satler, Michael J. Reardon, Steven J. Yakubov, Ron Waksman

Summary: Since the first transcatheter delivery of an aortic valve prosthesis in 2002, the treatment options for aortic stenosis (AS) have undergone significant changes. Transcatheter aortic valve replacement (TAVR) has become the frontline therapy for severe symptomatic AS, applicable to patients across all risk categories. However, there are still patients who are not suitable for TAVR due to certain anatomical and procedural factors. This study focuses on these scenarios and explores the reasons for referring selected patients for surgical aortic valve replacement in 2023.

AMERICAN JOURNAL OF CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Differences in Myocardial Remodeling and Tissue Characteristics in Chronic Isolated Aortic and Mitral Regurgitation

Maan Malahfji, Danai Kitkungvan, Alpana Senapati, Duc T. Nguyen, Carlos El-Tallawi, Bhupendar Tayal, Dany Debs, Valentina Crudo, Edward A. Graviss, Michael J. Reardon, Miguel Quinones, William A. Zoghbi, Dipan J. Shah

Summary: Cardiac magnetic resonance identified significant differences in remodeling patterns and tissue characteristics between patients with aortic regurgitation and primary mitral regurgitation. Aortic regurgitation led to more pronounced increases in ventricular volume and mass, while mitral regurgitation patients had normal geometry followed by myocardial thinning. Furthermore, mitral regurgitation patients had a higher prevalence of myocardial scarring and higher extracellular volume with increasing regurgitant volume.

CIRCULATION-CARDIOVASCULAR IMAGING (2023)

Article Cardiac & Cardiovascular Systems

Perioperative care differences of surgical aortic valve replacement between North America and Europe

Bart J. J. Velders, Michiel D. Vriesendorp, Rob A. F. De Lind Van Wijngaarden, Vivek Rao, Michael J. Reardon, Malakh Shrestha, Michael W. A. Chu, Joseph F. Sabik III, Fang Liu, Robert J. M. Klautz

Summary: This study compared the perioperative management of patients undergoing surgical aortic valve replacement (SAVR) between North America and Europe. The results showed that European patients were older, had lower body mass index, and more severe aortic stenosis at baseline. In Europe, anticoagulant therapy at discharge was more aggressive, length of stay was longer, and discharges directly to home were less common. Rehospitalisation risk differed between continents and countries.

HEART (2023)

Editorial Material Cardiac & Cardiovascular Systems

Indication Creep in Transcatheter Aortic Valve Implantation-Data or Desire?

Sachin S. Goel, Michael J. Reardon

JAMA CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Impact of aortic valve replacement in symptomatic low-risk patients with less than severe aortic stenosis

Saki Ito, Roger Laham, Vuyisile T. Nkomo, John K. Forrest, Michael J. Reardon, Stephen H. Little, Mubashir Mumtaz, Hemal Gada, Tanvir Bajwa, David Langholz, John Heiser, Atul Chawla, Bart Jenson, Guilherme Attizanni, Alan H. Markowitz, Jian Huang, Jae K. Oh

Summary: This study aimed to evaluate the impact of transcatheter or surgical aortic valve replacement (TAVR or SAVR) on clinical and haemodynamic outcomes in symptomatic patients with moderately-severe aortic stenosis (AS). The analysis showed that both TAVR and SAVR had significant effects on the treatment outcomes of symptomatic patients with moderately-severe AS.

OPEN HEART (2023)

Article Cardiac & Cardiovascular Systems

An Updated Meta-Analysis on Cerebral Embolic Protection in Patients Undergoing Transcatheter Aortic Valve Intervention Stratified by Baseline Surgical Risk and Device Type

Safi U. Khan, Salman Zahid, Mohamad A. Alkhouli, Usman Ali Akbar, Syed Zaid, Hassaan B. Arshad, Stephen H. Little, Michael J. Reardon, Neal S. Kleiman, Sachin S. Goel

Summary: The use of cerebral embolic protection (CEP) in patients undergoing transcatheter aortic valve intervention (TAVI) may reduce the risk of disabling stroke, especially in high and intermediate surgical risk patients.

STRUCTURAL HEART-THE JOURNAL OF THE HEART TEAM (2023)

Article Cardiac & Cardiovascular Systems

Predicting 5-Year Clinical Outcomes After Transcatheter or Surgical Aortic Valve Replacement (a Risk Score from the SURTAVI Trial)

Kees H. van Bergeijk, Joanna J. Wykrzykowska, Nicolas M. van Mieghem, Stephan Windecker, Lars Sondergaard, Hemal Gada, Shuzhen Li, Tim Hanson, Michael Deeb, Adriaan A. Voors, Michael J. Reardon

Summary: This study aimed to develop preprocedural risk scores for 5-year clinical outcomes after transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR). The risk predictors differed between TAVI and SAVR. The simple risk scoring systems performed better than the contemporary risk scores.

AMERICAN JOURNAL OF CARDIOLOGY (2023)

Letter Cardiac & Cardiovascular Systems

REPLY: Cardiac Remodeling in Aortic Regurgitation

Maan Malahfji, Duc T. Nguyen, Edward A. Graviss, Dipan J. Shah

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

Article Cardiac & Cardiovascular Systems

Transcatheter Aortic Valve Replacement in Large Annuli Valves With the Supra-Annular, Self-Expandable Evolut Platform in a Real-World Registry

Luis Augusto P. Dallan, Gilbert Tang, John K. Forrest, Michael J. Reardon, Wilson Y. Szeto, Susheel K. Kodali, Cristian Baeza, Ruth Eisenberg, Guilherme F. Attizzani

Summary: Research indicates that in transcatheter aortic valve replacement procedures, device oversizing within the range of >12% delivers better clinical outcomes compared to below-range (0%-12%) device oversizing, with lower mortality, reintervention, and readmission rates.

CIRCULATION-CARDIOVASCULAR INTERVENTIONS (2023)

No Data Available